Regulation (EC) No 726/2004
Regulation (EC) No 726/2004: Authorization and supervision of medicinal products for human use
Scope, objectives, and legal framework
EU Regulation and relationship to Union medicinal product law (EC/EU)
Regulation (EC) No 726/2004 is a directly applicable EU regulation and constitutes a central legislative act in European pharmaceutical law. This regulation governs the centralized Community procedure for the authorization and licensing of medicinal products within the Union and establishes a uniform system for medicinal products for human use. The objective of the regulation is the harmonized assessment, authorization, supervision, and monitoring of medicinal products at the European Union level. By means of these provisions, it is ensured that innovative and safety-relevant medicinal products are evaluated according to identical regulatory requirements and that their placement on the market within the EU is based on a uniform legal framework.
Distinction from EU Directives and National Regulations
In contrast to a directive, a regulation has direct legal effect in all member states of the Union. While the Community code relating to medicinal products for human use contains fundamental requirements, Regulation (EC) No 726/2004 defines the specific Community procedure for centralized EU authorization. National regulations remain applicable in a supplementary capacity but must not contradict the Union law requirements of this Regulation. This creates a clear hierarchy between the EU Regulation and national medicinal product law, thereby ensuring regulatory coherence within the EU.
Institutions & Roles in the Procedure
The European Medicines Agency (EMA) – Establishment, Tasks, Supervision
The European Medicines Agency (EMA) was established by the Regulation and serves as the central pharmaceutical agency of the EU. The organization coordinates the scientific evaluation process within the centralized Community procedure and manages the assessment of the quality, safety, and efficacy of medicinal products. The scientific review is primarily conducted by the Committee for Medicinal Products for Human Use (CHMP). In addition, the agency is responsible for European pharmacovigilance, including the EudraVigilance system, and undertakes the continuous monitoring of authorized medicinal products within the Union.
European Commission, Parliament, and Official Journal – Establishment and Publication of Decisions
The legally binding authorization and licensing of a medicinal product is granted by the European Commission based on the scientific recommendation of the Agency. The European Parliament, together with the Council, is involved in the amendment of the Regulation. Every authorization, modification, or withdrawal of a marketing authorization is published in the Official Journal of the European Union. Upon publication in the Official Journal, the decision attains Union-wide validity and becomes a binding component of EU law.
Centralized Community Procedure (Centralised Procedure)
Scope of Application for Medicinal Products for Human Use
The centralized Community procedure is mandatory for certain medicinal products for human use, particularly for biotechnologically manufactured medicines, orphan medicinal products, advanced therapy medicinal products (ATMPs), specific oncological active substances, as well as other innovative products. Through the centralized procedure, an EU-wide authorization is granted, enabling simultaneous placement on the market in all Member States and creating a uniform regulatory status.
Application, Dossier (CTD), Scientific Evaluation, and Authorization/Licensing
The authorization begins with the submission of a complete CTD dossier to the Agency. The dossier contains structured data regarding the manufacture, quality control, preclinical testing, and clinical evaluation of the medicinal product. Following validation, the scientific evaluation is conducted within specified timelines. The assessment culminates in a benefit-risk analysis, on the basis of which the Commission grants or refuses the EU authorization. This procedure ensures a transparent and standardized decision regarding licensing within the Union.
Placing on the Market in the EU: Validity, Conditions, Requirements, and Regulations
With the EU authorization, placing the medicinal product on the market is permitted in all Member States. The authorization may be subject to specific conditions, such as additional studies, risk minimization measures, or special monitoring requirements. National pricing and reimbursement decisions remain unaffected by the authorization. However, the Union-wide validity of the authorization creates a uniform legal basis for distribution within the EU.
Pharmacovigilance & Market Surveillance
Safety Monitoring/Pharmacovigilance, Risk Management, and Periodic Reports
The Regulation obligates marketing authorization holders to establish a comprehensive pharmacovigilance system. This includes an approved Risk Management Plan (RMP), the submission of Periodic Safety Update Reports (PSURs), and the reporting of adverse reactions via EudraVigilance. These regulatory provisions serve the continuous monitoring of medicinal products post-authorization and enable an ongoing assessment of the benefit-risk balance within the EU.
Measures in Case of Changes to the Benefit-Risk Assessment
If safety monitoring yields new findings, regulatory changes may become necessary. These changes can include updates to the Summary of Product Characteristics (SmPC), additional warnings, restrictions on use, or the suspension of the authorization. The decision is coordinated Union-wide to ensure a consistent risk assessment across all Member States.
Lifecycle-Management
Variations, Renewal, and Determination of Changes
Following authorization, every medicinal product is subject to structured lifecycle management in accordance with the Variations Regulation (EC) No 1234/2008. Variations concern, for example, changes in manufacturing, new indications, or adjustments to quality parameters. Prior to the expiry of the initial authorization period, a renewal is carried out based on updated safety and efficacy data. Any determination of changes requires formal approval by the competent EU authorities.
Batch Releases, Supply Obligations, and Supply Interruptions
Manufacturers and marketing authorization holders are obligated to ensure proper manufacturing, batch release, and market supply. Supply interruptions must be reported at an early stage. These regulatory requirements serve to secure stable supply chains and the continuous availability of authorized medicinal products within the Union.
Special Areas
Medicinal Products for Paediatric Use – Requirements, Study Plans, and Exemptions
Specific Union law requirements apply to medicinal products for paediatric use, in particular the submission of an approved Paediatric Investigation Plan (PIP). Study plans must be coordinated with the medicines agency prior to authorization. The objective of these regulations is to promote safe and effective medicinal products for human use for the paediatric population within the EU.
Interfaces with Other Legal Acts
Reference to Directive 2001/83/EC and other EU Regulations
The Regulation supplements Directive 2001/83/EC as well as other EU regulations in pharmaceutical law. While the Directive defines basic requirements for manufacturing and distribution, the Regulation governs the centralized authorization procedure at the EU level. This interplay ensures a systematic integration of Union law provisions.
Transitions, Updates, and Official Notices in the Official Journal
Amendments to the Regulation, updates to regulatory requirements, and new authorizations are published in the Official Journal. Transitional arrangements define deadlines for the implementation of new requirements. Publication ensures that market participants are informed of the current legal status at all times.
Obligations of Economic Operators
Manufacturers, Authorization Holders, Importers – Responsibilities
Manufacturers, importers, and authorization holders bear the responsibility for compliance with all regulatory requirements of the Regulation. This includes GMP-compliant manufacturing, quality assurance, documentation obligations, and ensuring full regulatory conformity throughout the entire product lifecycle.
Quality Management, Documentation, Reporting and Information Obligations
A robust quality management system is a prerequisite for maintaining the authorization. Companies must keep regulatory documentation up to date, fulfill reporting obligations, and transmit relevant information to the competent authorities without delay. These requirements ensure transparency, traceability, and compliance within the European pharmaceutical sector.
Testing and Verification Reference (Our Services)
Analytical Support for Non-clinical Development, Lead Discovery
The search for target molecules and structures for the development of new active ingredients requires analytical support for extraction processes, the identification and discovery of metabolites, and chemical structure elucidation. SAS hagmann supports pharmaceutical companies within the framework of R&D partnerships with services in the field of chemical analysis.
Quality/Safety/Efficacy: Analytical Testing, Stability, Vigilance Support
Analytical testing, monitoring of delivery systems regarding critical analytes, stability studies, and regulatory vigilance support ensure the sustained assurance of quality, safety, and efficacy. These services assist companies in complying with Union legal regulations, in amending existing authorizations, and in the long-term regulatory monitoring of their medicinal products within the EU.
